04:19:35 EDT Sat 15 May 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:MRK from 2020-05-15 to 2021-05-14 - 154 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2021-05-13 06:45U:MRKNews ReleaseMerck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
2021-05-07 13:01U:MRKNews ReleaseMerck Declares Record Date and Dividend for the Organon & Co. Spinoff
2021-05-06 06:45U:MRKNews ReleaseMerck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
2021-05-06 06:30U:MRKNews ReleaseMerck and Eisai Receive Priority Review From FDA for KEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
2021-05-05 16:05U:MRKNews ReleaseFDA Approves Merck ’s KEYTRUDA ® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
2021-05-03 06:45U:MRKNews ReleaseMerck Hosts Organon Investor Day Outlining New Company ’s Vision, Focus and Business Model for Sustained Growth
2021-04-29 06:30U:MRKNews ReleaseMerck Announces First-Quarter 2021 Financial Results
2021-04-27 06:47U:MRKNews ReleaseMerck to Hold Investor Briefing Featuring Organon on May 3
2021-04-27 06:45U:MRKNews ReleaseAmid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19
2021-04-26 06:45U:MRKNews ReleaseMerck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025
2021-04-15 06:46U:MRKNews ReleaseMerck to Discontinue Development of MK-7110 for COVID-19
2021-04-15 06:45U:MRKNews ReleaseMerck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
2021-04-14 08:00U:MRKNews ReleaseMerck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week
2021-04-08 20:31U:MRKNews ReleaseOrganon Announces Pricing of Senior Notes Offering
2021-04-08 06:45U:MRKNews ReleaseMerck ’s KEYTRUDA ® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery
2021-04-06 16:10U:MRKNews ReleaseOrganon Announces Proposed Senior Notes Offering
2021-04-01 08:30U:MRKNews ReleaseMerck Completes Acquisition of Pandion Therapeutics
2021-03-30 07:30U:MRKNews ReleaseMerck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
2021-03-30 06:45U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA ® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial Cancer
2021-03-29 16:15U:MRKNews ReleaseMerck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
2021-03-29 06:45U:MRKNews ReleaseMerck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
2021-03-24 06:45U:MRKNews ReleaseMerck Appoints Caroline Litchfield Chief Financial Officer
2021-03-23 06:45U:MRKNews ReleaseFDA Approves Merck ’s KEYTRUDA ® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
2021-03-19 06:45U:MRKNews ReleaseKEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study
2021-03-17 16:27U:MRKNews ReleaseMerck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co.
2021-03-17 07:00U:MRKNews ReleaseEuropean Commission Approves Expanded Indication for Merck ’s KEYTRUDA ® (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
2021-03-17 06:45U:MRKNews ReleaseMike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health
2021-03-16 06:45U:MRKNews ReleaseMerck Receives Priority Review From FDA for New Drug Application for HIF-2a Inhibitor Belzutifan (MK-6482)
2021-03-15 06:47U:MRKNews ReleaseMerck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead
2021-03-15 06:45U:MRKNews ReleaseGilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
2021-03-08 11:40U:MRKNews ReleaseMerck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021
2021-03-08 07:00U:MRKNews ReleaseHealth Canada Approves KEYTRUDA ® (pembrolizumab) as First-line Treatment for Adults with Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
2021-03-06 00:01U:MRKNews ReleaseRidgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
2021-03-04 06:45U:MRKNews ReleaseMerck Begins Tender Offer to Acquire Pandion Therapeutics
2021-03-03 06:45U:MRKNews ReleaseMerck to Present at the Barclays Global Healthcare Conference
2021-03-03 06:45U:MRKNews ReleaseMerck to Present New Data from Various HIV Research and Development Programs at CROI 2021
2021-03-02 16:30U:MRKNews ReleaseMerck to Help Produce Johnson & Johnson ’s COVID-19 Vaccine; BARDA to Provide Merck With Funding to Expand Merck ’s Manufacturing Capacity for COVID-19 Vaccines and Medicines
2021-03-02 08:00U:MRKNews ReleaseMerck Announces Fifth Round of Global Grants to Tackle Maternal Mortality and Promote Health Equity Worldwide
2021-03-01 16:05U:MRKNews ReleaseMerck Provides Update on KEYTRUDA ® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US
2021-03-01 06:45U:MRKNews ReleaseU.S. FDA Accepts Merck ’s Gefapixant New Drug Application for Review
2021-02-25 16:30U:MRKNews ReleaseMerck Animal Health Completes Acquisition of Poultry Sense Limited
2021-02-25 15:05U:MRKNews ReleaseSHAREHOLDER ALERT: WeissLaw LLP Investigates Pandion Therapeutics, Inc.
2021-02-25 06:45U:MRKNews ReleaseMerck to Acquire Pandion Therapeutics
2021-02-24 06:45U:MRKNews ReleaseMerck to Present at the Cowen 41st Annual Health Care Conference
2021-02-17 06:55U:MRKNews ReleaseIndependent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA ® (olaparib) Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis
2021-02-13 13:01U:MRKNews ReleaseKEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
2021-02-04 06:45U:MRKNews ReleaseMerck Announces Fourth-Quarter and Full-Year 2020 Financial Results
2021-02-04 06:40U:MRKNews ReleaseKenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman
2021-02-01 06:45U:MRKNews ReleaseDr. Stephen Mayo Elected to Merck Board of Directors
2021-02-01 06:30U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA ® (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
2021-01-29 19:23U:MRKNews ReleaseMerck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA ® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer
2021-01-27 08:00U:MRKNews ReleaseMerck Announces Second Cohort of Safer Childbirth Cities Organizations Committed to Improving Maternal Health Equity and Reducing Preventable Maternal Deaths in the US
2021-01-26 13:15U:MRKNews ReleaseMerck Announces Second-Quarter 2021 Dividend
2021-01-26 09:06U:MRKNews ReleaseMerck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021
2021-01-26 06:45U:MRKNews ReleaseEuropean Commission Approves KEYTRUDA ® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
2021-01-25 06:45U:MRKNews ReleaseMerck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates
2021-01-20 09:00U:MRKNews ReleaseMerck Canada and MaRS Team Up to Launch Lung Cancer Innovation Challenge
2021-01-20 06:45U:MRKNews ReleaseMerck Announces U.S. FDA Approval of VERQUVO ® (vericiguat)
2021-01-12 06:45U:MRKNews ReleaseU.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck ’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older
2021-01-08 06:45U:MRKNews ReleaseMerck to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference Call on February 4
2021-01-04 06:45U:MRKNews ReleaseMerck to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-28 06:45U:MRKNews ReleaseLYNPARZA ® (olaparib) Receives Three New Approvals in Japan
2020-12-16 06:45U:MRKNews ReleaseKEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced...
2020-12-11 07:10U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for KEYTRUDA ® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
2020-11-30 06:45U:MRKNews ReleaseMerck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Conference
2020-11-23 09:06U:MRKNews ReleaseMerck Animal Health Survey Reveals First-Time Dog Owners Need Support
2020-11-23 06:47U:MRKNews ReleaseMerck Submits Applications for Licensure of V114, the Company ’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency
2020-11-23 06:45U:MRKNews ReleaseMerck to Acquire OncoImmune
2020-11-17 13:25U:MRKNews ReleaseMerck Announces First-Quarter 2021 Dividend
2020-11-16 06:45U:MRKNews ReleaseMerck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
2020-11-13 16:10U:MRKNews ReleaseFDA Approves Merck ’s KEYTRUDA ® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS =10)
2020-11-09 16:10U:MRKNews ReleaseMerck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA ® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue...
2020-11-05 06:52U:MRKNews ReleasePappas Capital Portfolio Company VelosBio to be Acquired by Merck
2020-11-05 06:45U:MRKNews ReleaseLYNPARZA ® (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2020-11-05 06:45U:MRKNews ReleaseLYNPARZA ® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer
2020-11-05 06:30U:MRKNews ReleaseMerck to Acquire VelosBio
2020-10-20 06:45U:MRKNews ReleaseMerck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck ’s Investigational 15-valent Pneumococcal Conjugate Vaccine
2020-10-16 14:00U:MRKNews ReleaseMerck Presents Three-Year Survival Data for KEYTRUDA ® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non-Small Cell Lung Cancer
2020-10-15 07:00U:MRKNews ReleaseHealth Canada Approves KEYTRUDA ® (pembrolizumab) as First-line Treatment for Patients with Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
2020-10-15 06:45U:MRKNews ReleaseFDA Approves Expanded Indication for Merck ’s KEYTRUDA ® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
2020-10-14 08:00U:MRKNews ReleaseMerck Issues 2019/2020 Corporate Responsibility Report
2020-10-08 06:45U:MRKNews ReleaseMerck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection
2020-10-02 08:00U:MRKNews ReleaseMerck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories
2020-10-01 06:45U:MRKNews ReleaseMerck to Present New Data from the Company ’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020
2020-10-01 06:30U:MRKNews ReleaseMerck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27
2020-09-28 06:45U:MRKNews ReleaseMerck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day
2020-09-24 07:00U:MRKNews ReleaseNEXPLANON ® Contraceptive Arm Implant Now Available for Use in Canada
2020-09-21 12:30U:MRKNews ReleaseMerck ’s KEYTRUDA ® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer
2020-09-21 08:25U:MRKNews ReleaseFirst-Line Treatment With Merck ’s KEYTRUDA ® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS >50%)
2020-09-21 06:45U:MRKNews ReleaseLYNPARZA ® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2020-09-21 06:45U:MRKNews ReleaseLYNPARZA ® (olaparib) Recommended for Approval in EU by CHMP as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
2020-09-20 12:30U:MRKNews ReleaseLYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abiraterone in Phase 3 PROfound Trial
2020-09-20 10:20U:MRKNews ReleaseMerck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020
2020-09-20 08:25U:MRKNews ReleaseMerck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
2020-09-19 10:20U:MRKNews ReleaseMerck ’s KEYTRUDA ® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
2020-09-18 06:45U:MRKNews ReleaseLYNPARZA ® (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
2020-09-16 06:45U:MRKNews ReleaseMerck to Hold Investor Briefing Following ESMO Virtual Congress 2020
2020-09-15 07:00U:MRKNews ReleaseBRENZYS ® (etanercept injection) now indicated for the Treatment of Plaque Psoriasis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis
2020-09-15 06:45U:MRKNews ReleaseMerck to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
2020-09-10 06:45U:MRKNews ReleaseMerck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference
2020-09-09 06:45U:MRKNews ReleaseMerck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck ’s Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial
2020-09-08 06:45U:MRKNews ReleaseMerck ’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough
2020-09-08 06:30U:MRKNews ReleaseBiopharma Leaders Unite to Stand with Science
2020-09-08 06:30U:MRKNews ReleaseBiopharma Leaders Unite To Stand With Science
2020-09-08 06:30U:MRKNews ReleaseBiopharma Leaders Unite to Stand with Science
2020-09-04 06:45U:MRKNews ReleaseMerck to Present at the Citi 15th Annual BioPharma Virtual Conference
2020-09-02 06:45U:MRKNews ReleaseNew Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck ’s Commitment to Advancing Cancer Research and Care
2020-09-01 09:00U:MRKNews ReleaseTriRx Pharmaceutical Services acquires MSD Animal Health manufacturing site located in Segr ©-en Anjou Bleu, France including long-term supply agreement
2020-08-24 06:45U:MRKNews ReleaseMerck ’s KEYTRUDA ® (pembrolizumab) Receives Two New Approvals in Japan
2020-08-19 06:45U:MRKNews ReleaseMerck ’s KEYTRUDA ® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer
2020-08-13 03:54U:MRKNews ReleaseQBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma
2020-08-11 06:30U:MRKNews ReleaseSurface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020
2020-08-05 07:00U:MRKNews ReleaseMerck Animal Health Completes Acquisition of IdentiGEN
2020-08-04 05:00U:MRKNews ReleaseMerck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)
2020-08-03 06:30U:MRKNews ReleaseMerck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN ® Brand of Parasiticides for Ruminant Portfolio
2020-07-31 06:45U:MRKNews Release  Merck Announces Second-Quarter 2020 Financial Results
2020-07-30 06:45U:MRKNews ReleaseMerck Announces Two US Regulatory Milestones for KEYTRUDA ® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)
2020-07-29 06:45U:MRKNews ReleaseFDA Grants Breakthrough Therapy Designation to Merck ’s Novel HIF-2a Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
2020-07-28 13:30U:MRKNews ReleaseMerck Announces Fourth-Quarter 2020 Dividend
2020-07-16 06:45U:MRKNews ReleaseFDA Grants Priority Review to Merck ’s New Drug Application for Vericiguat
2020-07-09 16:30U:MRKNews ReleaseMerck Animal Health Receives U.S. FDA Approval of BRAVECTO ® (fluralaner) Monthly Chews
2020-07-09 06:45U:MRKNews ReleaseFDA Grants Priority Review to Merck ’s Supplemental Biologics License Application for KEYTRUDA ® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
2020-07-08 16:30U:MRKNews ReleaseMerck Announces Appointment of Organon & Co. General Counsel
2020-07-08 06:55U:MRKNews ReleaseLYNPARZA ® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer
2020-07-06 06:45U:MRKNews ReleaseMerck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
2020-07-02 02:00U:MRKNews ReleaseMerck Animal Health Completes Acquisition of U.S. Rights to SENTINEL ® Brand of Combination Parasiticides for Companion Animals
2020-07-01 16:30U:MRKNews ReleaseMerck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction
2020-07-01 06:45U:MRKNews ReleaseMerck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31
2020-06-29 16:20U:MRKNews ReleaseFDA Approves Merck ’s KEYTRUDA ® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
2020-06-24 17:29U:MRKNews ReleaseFDA Approves Merck ’s KEYTRUDA ® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
2020-06-24 06:45U:MRKNews ReleaseMerck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
2020-06-22 06:45U:MRKNews ReleaseMerck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults
2020-06-22 06:30U:MRKNews ReleaseMerck ’s KEYTRUDA ® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS =10)
2020-06-19 08:29U:MRKNews ReleaseMerck Completes Acquisition of Themis
2020-06-17 16:30U:MRKNews ReleaseMerck Animal Health Completes Acquisition of Quantified Ag ®
2020-06-17 06:45U:MRKNews ReleaseFDA Approves Second Biomarker-Based Indication for Merck ’s KEYTRUDA ® (pembrolizumab), Regardless of Tumor Type
2020-06-17 06:30U:MRKNews ReleaseMerck Prices $4.5 Billion Debt Offering
2020-06-16 13:15U:MRKNews ReleaseMerck and Pfizer ’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
2020-06-15 08:00U:MRKNews ReleaseMerck Announces Call for Proposals for Second Cohort of Safer Childbirth Cities, Expanding Maternal Health Support Across US Cities
2020-06-12 18:40U:MRKNews ReleaseFDA Approves Merck ’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
2020-06-09 16:05U:MRKNews ReleaseMerck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA ® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma
2020-06-05 06:50U:MRKNews ReleaseFDA Approves Merck ’s RECARBRIO ™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
2020-06-01 06:45U:MRKNews ReleaseLYNPARZA ® (olaparib) Receives Positive Opinion from EU CHMP for First-Line Maintenance Treatment of Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer
2020-05-28 18:37U:MRKNews ReleaseKEYTRUDA ® (pembrolizumab) plus LENVIMA ® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma
2020-05-28 17:00U:MRKNews ReleaseMerck ’s KEYTRUDA ® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
2020-05-26 12:37U:MRKNews ReleaseMerck Announces Third-Quarter 2020 Dividend
2020-05-26 06:51U:MRKNews ReleaseMerck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
2020-05-26 06:49U:MRKNews ReleaseIAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
2020-05-26 06:47U:MRKNews ReleaseMerck to Acquire Themis
2020-05-26 06:45U:MRKNews ReleaseMerck to Announce Multiple Scientific Efforts to Combat COVID-19
2020-05-20 07:05U:MRKNews ReleaseSurface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA ® (pembrolizumab) in Solid Tumor Patients
2020-05-20 06:55U:MRKNews ReleaseLYNPARZA ® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
2020-05-19 07:00U:MRKNews Release  Infectious Disease Connect and IL šM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship
2020-05-18 13:30U:MRKNews ReleaseCORRECTING and REPLACING Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer